AZ’s anselamimab fails to meet primary endpoint in amyloidosis trial
High-level results from the Cardiac Amyloid Reaching for Extended Survival (CARES) Phase III clinical programme show that anselamimab did not achieve statistical significance for the primary endpoint compared to placebo in patients with Mayo stages IIIa and IIIb light chain (AL) amyloidosis.
The primary endpoint was defined as a hierarchical combination of time to all-cause mortality (ACM) and frequency of cardiovascular hospitalisations (CVH).
The company states that all patients in the clinical programme received background standard of care for plasma cell dyscrasia.
However, anselamimab did show highly clinically meaningful improvement in time to ACM and frequency of CVH in a prespecified subgroup of patients, compared to placebo.
AL amyloidosis is caused by defective plasma cells in the bone marrow. Abnormal light chain proteins produced by these plasma cells misfold, aggregate and form amyloid fibrils that deposit in tissues and organs.
Left untreated, the accumulation of these toxic amyloid deposits can cause progressive organ damage and dysfunction and may lead to premature death.
Ashutosh Wechalekar, Consultant Haematologist at University College London Hospitals NHS Foundation Trust (UCLH), Professor of Medicine and Haematology at University College London (UCL) and lead principal investigator of the programme, said: “While the study did not meet the primary endpoint in the overall patient population, results from a pre-defined subgroup suggest that anselamimab, by targeting and clearing amyloid deposits, may address a leading cause of organ damage and functional impairment in these patients. The potential to extend survival and reduce cardiovascular hospitalisations would represent a practice-changing advancement for this patient group.”
Marc Dunoyer, Chief Executive Officer, Alexion, AstraZeneca Rare Disease, added: “Anselamimab is the first and only investigational fibril depleter to show clinical benefit in AL amyloidosis, and these results underscore its potential to address a critical treatment gap in a prespecified subgroup of patients.”
Diana Turner, Senior Digital Content Editor, DDW
